Citigroup’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Citigroup’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65,000	Closed	-$5.91M	–	5816
2023 Q1	$5.91M	Buy	+65,000	New	+$3.81M	﹤0.01%	1413

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's RETA Position: Q3 2023 in Review

Citigroup sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 16,422 shares — an estimated $1.67M sold.

Citigroup first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $4.04M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Citigroup reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Citigroup sold 16,422 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.67M.
Citigroup first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
Citigroup's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.04M in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.